Obesity and diabetes cure? CRISPR might be used to ‘silence’ key gene found in unhealthy fat

| | September 12, 2019
obesity
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

The gene FABP4 is highly active in adipose tissue and known to be a major contributor to obesity and related diseases like type 2 diabetes. Researchers at Hanyang University in Seoul have developed a way to silence the gene using a type of gene-editing technology called CRISPR interference.

When the researchers inhibited FABP4 in white adipose tissue—commonly known as the unhealthy white fat—they observed a reduction in lipid storage.

Then they tried it in mice that had been fed a high-fat diet, injecting them twice a week with the CRISPR interference system. The mice lost 20% of their body weight and showed reductions in inflammation and insulin resistance, the team reported in the journal Genome Research.

Related article:  Viewpoint: Costly regulations prevent consumers from enjoying benefits of biotech crops

Researchers continue to look for weight-loss strategies that might be more effective than the current slate of FDA-approved drugs. Those products—Eisai’s Belviq, Nalpropion’s Contrave and Vivus’ Qsymia—have only been shown to reduce body weight by a small percentage.

The Hanyang University team is planning further studies to determine how best to translate their gene therapy to people with obesity. They believe that similar “precision gene-editing technology” could be used to treat other diseases.

Read full, original post: Could gene therapy be the solution to obesity and diabetes?

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend